We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Ixico Plc | LSE:IXI | London | Ordinary Share | GB00BFXR4C20 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 8.75 | 8.50 | 9.00 | 8.75 | 8.725 | 8.75 | 4,640 | 08:00:07 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMIXI
RNS Number : 1763Z
IXICO plc
30 August 2018
30(th) August 2018
IXICO plc
("IXICO" or the "Company")
Expansion of contract with biopharmaceutical company
Total contract value has increased to EUR1.3m
IXICO plc (AIM: IXI), the data science company delivering insights in neuroscience, today announced that it has signed a further change order to a current contract which increases the total contract value to EUR1.3m.
The original contract in Alzheimer's disease was announced on 5 July 2017 and this change order reflects an extension of the contract term from September 2020 to May 2021 and the addition of new clinical sites. The latest amendment results in a total change in the contract value of EUR0.5m or 65% above the original value of EUR0.8m.
Change orders often occur as part of the normal course of multi-year contracts, as the scope of services that IXICO provides can be expanded or extended during the term of a clinical trial.
Giulio Cerroni, Chief Executive Officer of IXICO, said: "We are delighted to announce a further extension and expansion of this project. This change order and increase in contract value, demonstrates how closely we work with our biopharmaceutical clients to expand the services we provide to their clinical development programmes."
For further information please contact:
IXICO plc Giulio Cerroni, Chief Executive Officer Tel: +44 20 3763 7499 Susan Lowther, Chief Financial Officer Shore Capital (Nomad and Broker) Tel: +44 20 7408 4090 Edward Mansfield/Anita Ghanekar/Daniel Bush FTI Consulting Limited (Investor Relations) Tel: +44 20 3727 1000 Simon Conway/Mo Noonan
About IXICO
IXICO is dedicated to delivering insights in neuroscience. Our mission is to transform the progression of our clients' neurodegenerative therapeutic pipeline through the application of novel medical imaging and mobile health digital technologies.
IXICO's specialist data analytics services are used by the global pharmaceutical industry to interpret brain scan data and digital biomarkers to enable better trial design, site qualification, patient selection and clinical outcomes. We provide technology-enabled services across all phases of clinical trial process evaluation. Our integrated digital platform provides a scalable and secure infrastructure for the capture and analysis of regulatory compliant clinical data to enable clients to make rapid, better informed decisions. IXICO is also collaborating with partners to develop new analytical techniques and companion digital health products.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
CNTEALPNAAAPEFF
(END) Dow Jones Newswires
August 30, 2018 02:00 ET (06:00 GMT)
1 Year Ixico Chart |
1 Month Ixico Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions